Birch pollen allergy vaccine - Anergis

Drug Profile

Birch pollen allergy vaccine - Anergis

Alternative Names: AllerT; AllerT-Birch

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Lausanne
  • Developer Anergis
  • Class Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 26 Sep 2017 Anergis completes a phase II trial in Allergic rhinoconjunctivitis in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden (NCT02943720)
  • 06 Sep 2017 Efficacy and adverse events data from a phase II trial in Allergic rhinoconjunctivitis released by Anergis
  • 03 Mar 2017 Immunogenicity data from a phase II trial in Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top